Impact of Bone Metastases on Patients with Renal Cell Carcinoma or Melanoma Treated with Combotherapy Ipilimumab Plus Nivolumab

(1) Background: Ipilimumab plus nivolumab (combo-ICI) improves overall survival (OS) in patients with advanced renal cell carcinoma (RCC) or melanoma. The impact of bone metastases (BM) on survival outcomes of combo-ICI-treated patients is unknown. (2) Methods: This single-center retrospective obser...

Descripción completa

Detalles Bibliográficos
Autores principales: Pham, Félix, Belkaid, Samy, Maillet, Denis, Confavreux, Cyrille B., Dalle, Stéphane, Péron, Julien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687259/
https://www.ncbi.nlm.nih.gov/pubmed/36359278
http://dx.doi.org/10.3390/biomedicines10112758

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687259/
https://www.ncbi.nlm.nih.gov/pubmed/36359278
http://dx.doi.org/10.3390/biomedicines10112758

Ejemplares similares